Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom

Background: The United Kingdom (UK) switched from using the 4-valent human papillomavirus (HPV) vaccine (Gardasil®) to the 9-valent vaccine (Gardasil 9®) in 2021. Objective: To estimate and compare the health and economic outcomes of 2 HPV vaccination programs in the UK targeting girls and boys aged...

Descripción completa

Detalles Bibliográficos
Autores principales: Owusu-Edusei, Kwame, Palmer, Cody, Ovcinnikova, Olga, Favato, Giampiero, Daniels, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2022
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170517/
https://www.ncbi.nlm.nih.gov/pubmed/35795155
http://dx.doi.org/10.36469/001c.34721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170517/
https://www.ncbi.nlm.nih.gov/pubmed/35795155
http://dx.doi.org/10.36469/001c.34721

Ejemplares similares